STUDY OF DISPARITIES BETWEEN SERUM LDH AND SOLUBLE INTERLEUKIN-2 RECEPTOR (SIL-2R) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS
(Abstract release date: 05/19/16)
EHA Library. Okatani T. 06/09/16; 134641; PB1741
Dr. Takeshi Okatani
Contributions
Contributions
Abstract
Abstract: PB1741
Type: Publication Only
Background
Serum LDH or serum interleukin-2 receptor (sIL-2R) are two of the most important tumour markers of malignant lymphoma, and of diffuse large B-cell lymphoma (DLBCL), which is the most common histological types of non-Hodgkin lymphoma. We usually find elevated values of both in DLBCL patients; however, sometimes there are cases where, unexpectedly, only one value does not exhibit an abnormal level, while the other does.
Aims
To analyse the clinical characteristics of cases where serum LDH and sIL-2R are not correlated.
Methods
We retrospectively analysed 556 patients that visited our hospital from March 1994 to June 2012 and who were diagnosed for the first time as having DLBCL. We drew a distribution chart of the ratio of serum LDH and normal level (LDH / N) and serum sIL-2R. (Figure 1.) The median LDH/N was 1.04 (0.38-20.59), and sIL-2R was 1,420 (119-40,000). Then, we decided two groups; group I was LDH / N >2, sIL-2R <2,000U/ml, and group II was LDH / N <1, sIL-2R >3,000U/ml.
Results
The median age of the DLBCL patients was 67 years (19-97). Thirteen patients were in group I (six female and seven male), and a total of 13 patients were diagnosed as being at an advanced clinical stage of disease. There were five patients aged over 60 (38%), but there were nine cases (69%) in which Performance Status (PS) was over 2. Twelve patients (92%) belonged to the higher-risk group, in which International Prognostic Index (IPI) was over 3. As for incidence, there were four (31%), primary mediastinal cases, seven (54%) extra-nodal onset cases, and bulky mass was observed in nine (69%). We were able to review six cases for pathological diagnosis; three were of the GCB type and three were the non-GCB type. On the other hand, 15 patients were in group II (seven female and eight male), 10 cases (67%) were over 60 years of age, but there were only four (27%) cases in which PS was over 2, and finally there were three (20%) in the higher-risk group. Ten cases (67%) had retroperitoneal mass and seven (47%) showed bone marrow involvement. Pathological diagnosis could be reviewed again in six cases; two were the GCB type and four were non-GCB type.
Conclusion
DLBCL is a heterogenous disease. By analysing cases of disparity biomarkers between LDH and sIL-2R, we showed the possibility of identifying subgroups.
Session topic: E-poster
Keyword(s): Diffuse large B cell lymphoma
Type: Publication Only
Background
Serum LDH or serum interleukin-2 receptor (sIL-2R) are two of the most important tumour markers of malignant lymphoma, and of diffuse large B-cell lymphoma (DLBCL), which is the most common histological types of non-Hodgkin lymphoma. We usually find elevated values of both in DLBCL patients; however, sometimes there are cases where, unexpectedly, only one value does not exhibit an abnormal level, while the other does.
Aims
To analyse the clinical characteristics of cases where serum LDH and sIL-2R are not correlated.
Methods
We retrospectively analysed 556 patients that visited our hospital from March 1994 to June 2012 and who were diagnosed for the first time as having DLBCL. We drew a distribution chart of the ratio of serum LDH and normal level (LDH / N) and serum sIL-2R. (Figure 1.) The median LDH/N was 1.04 (0.38-20.59), and sIL-2R was 1,420 (119-40,000). Then, we decided two groups; group I was LDH / N >2, sIL-2R <2,000U/ml, and group II was LDH / N <1, sIL-2R >3,000U/ml.
Results
The median age of the DLBCL patients was 67 years (19-97). Thirteen patients were in group I (six female and seven male), and a total of 13 patients were diagnosed as being at an advanced clinical stage of disease. There were five patients aged over 60 (38%), but there were nine cases (69%) in which Performance Status (PS) was over 2. Twelve patients (92%) belonged to the higher-risk group, in which International Prognostic Index (IPI) was over 3. As for incidence, there were four (31%), primary mediastinal cases, seven (54%) extra-nodal onset cases, and bulky mass was observed in nine (69%). We were able to review six cases for pathological diagnosis; three were of the GCB type and three were the non-GCB type. On the other hand, 15 patients were in group II (seven female and eight male), 10 cases (67%) were over 60 years of age, but there were only four (27%) cases in which PS was over 2, and finally there were three (20%) in the higher-risk group. Ten cases (67%) had retroperitoneal mass and seven (47%) showed bone marrow involvement. Pathological diagnosis could be reviewed again in six cases; two were the GCB type and four were non-GCB type.
Conclusion
DLBCL is a heterogenous disease. By analysing cases of disparity biomarkers between LDH and sIL-2R, we showed the possibility of identifying subgroups.
Session topic: E-poster
Keyword(s): Diffuse large B cell lymphoma
Abstract: PB1741
Type: Publication Only
Background
Serum LDH or serum interleukin-2 receptor (sIL-2R) are two of the most important tumour markers of malignant lymphoma, and of diffuse large B-cell lymphoma (DLBCL), which is the most common histological types of non-Hodgkin lymphoma. We usually find elevated values of both in DLBCL patients; however, sometimes there are cases where, unexpectedly, only one value does not exhibit an abnormal level, while the other does.
Aims
To analyse the clinical characteristics of cases where serum LDH and sIL-2R are not correlated.
Methods
We retrospectively analysed 556 patients that visited our hospital from March 1994 to June 2012 and who were diagnosed for the first time as having DLBCL. We drew a distribution chart of the ratio of serum LDH and normal level (LDH / N) and serum sIL-2R. (Figure 1.) The median LDH/N was 1.04 (0.38-20.59), and sIL-2R was 1,420 (119-40,000). Then, we decided two groups; group I was LDH / N >2, sIL-2R <2,000U/ml, and group II was LDH / N <1, sIL-2R >3,000U/ml.
Results
The median age of the DLBCL patients was 67 years (19-97). Thirteen patients were in group I (six female and seven male), and a total of 13 patients were diagnosed as being at an advanced clinical stage of disease. There were five patients aged over 60 (38%), but there were nine cases (69%) in which Performance Status (PS) was over 2. Twelve patients (92%) belonged to the higher-risk group, in which International Prognostic Index (IPI) was over 3. As for incidence, there were four (31%), primary mediastinal cases, seven (54%) extra-nodal onset cases, and bulky mass was observed in nine (69%). We were able to review six cases for pathological diagnosis; three were of the GCB type and three were the non-GCB type. On the other hand, 15 patients were in group II (seven female and eight male), 10 cases (67%) were over 60 years of age, but there were only four (27%) cases in which PS was over 2, and finally there were three (20%) in the higher-risk group. Ten cases (67%) had retroperitoneal mass and seven (47%) showed bone marrow involvement. Pathological diagnosis could be reviewed again in six cases; two were the GCB type and four were non-GCB type.
Conclusion
DLBCL is a heterogenous disease. By analysing cases of disparity biomarkers between LDH and sIL-2R, we showed the possibility of identifying subgroups.
Session topic: E-poster
Keyword(s): Diffuse large B cell lymphoma
Type: Publication Only
Background
Serum LDH or serum interleukin-2 receptor (sIL-2R) are two of the most important tumour markers of malignant lymphoma, and of diffuse large B-cell lymphoma (DLBCL), which is the most common histological types of non-Hodgkin lymphoma. We usually find elevated values of both in DLBCL patients; however, sometimes there are cases where, unexpectedly, only one value does not exhibit an abnormal level, while the other does.
Aims
To analyse the clinical characteristics of cases where serum LDH and sIL-2R are not correlated.
Methods
We retrospectively analysed 556 patients that visited our hospital from March 1994 to June 2012 and who were diagnosed for the first time as having DLBCL. We drew a distribution chart of the ratio of serum LDH and normal level (LDH / N) and serum sIL-2R. (Figure 1.) The median LDH/N was 1.04 (0.38-20.59), and sIL-2R was 1,420 (119-40,000). Then, we decided two groups; group I was LDH / N >2, sIL-2R <2,000U/ml, and group II was LDH / N <1, sIL-2R >3,000U/ml.
Results
The median age of the DLBCL patients was 67 years (19-97). Thirteen patients were in group I (six female and seven male), and a total of 13 patients were diagnosed as being at an advanced clinical stage of disease. There were five patients aged over 60 (38%), but there were nine cases (69%) in which Performance Status (PS) was over 2. Twelve patients (92%) belonged to the higher-risk group, in which International Prognostic Index (IPI) was over 3. As for incidence, there were four (31%), primary mediastinal cases, seven (54%) extra-nodal onset cases, and bulky mass was observed in nine (69%). We were able to review six cases for pathological diagnosis; three were of the GCB type and three were the non-GCB type. On the other hand, 15 patients were in group II (seven female and eight male), 10 cases (67%) were over 60 years of age, but there were only four (27%) cases in which PS was over 2, and finally there were three (20%) in the higher-risk group. Ten cases (67%) had retroperitoneal mass and seven (47%) showed bone marrow involvement. Pathological diagnosis could be reviewed again in six cases; two were the GCB type and four were non-GCB type.
Conclusion
DLBCL is a heterogenous disease. By analysing cases of disparity biomarkers between LDH and sIL-2R, we showed the possibility of identifying subgroups.
Session topic: E-poster
Keyword(s): Diffuse large B cell lymphoma
{{ help_message }}
{{filter}}